Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
70 Results for "
Potential substrate
" in MedChemExpress (MCE) Product Catalog:
Products (70)
70 Results for "Potential substrate" in MCE Product Catalog:
Cat. No.: HY-149425
CAS No.: 2834736-82-0
Target:
Research Areas:
SIRT5 Inhibitor 6 is a potent, substrate-competitive and selective SIRT5 inhibitor with an IC50 of 3.0 μM. SIRT5 Inhibitor6 has a therapeutic potential against septic AKI in vivo .
Cat. No.: HY-171195
CAS No.: 1235656-95-7
Target:
Research Areas:
VU0631019 is a potent antagonist of 5-HT2B, with the IC50 of 29 nM. VU0631019 is predicted to have very limited potential for brain penetration in human subjects, as is predicted to be substrates for P-gp-mediated efflux in humans .
Cat. No.: HY-119172R
CAS No.: 70-09-7
Target:
Research Areas:
NSC-60339 (Standard) is the analytical standard of NSC-60339. This product is intended for research and analytical applications. NSC-60339, an efflux pump inhibitor and a substrate of AcrAB-TolC, is a polybasic terephthalic acid derivative studied as a potential cancer chemotherapeutic agent .
Cat. No.: HY-171194
CAS No.: 1396886-30-8
Target:
Research Areas:
VU0530244 is a potent antagonist of 5-HT2B, with the IC50 of 17.3 nM. VU0530244 is predicted to have very limited potential for brain penetration in human subjects, as is predicted to be substrates for P-gp-mediated efflux in humans .
Cat. No.: HY-W777429
CAS No.: 634151-16-9
Cat. No.: HY-163292
CAS No.: 3029324-01-1
Antibacterial agent 180 (15g), an appropriate substrate for the type I nitro reductases (TcNTR I), is a promising antitrypanosomatid agent. Antibacterial agent 180 (15g) shows nonmutagenic potential against Salmonella typhimurium strains (TA98, TA100, and TA102) .
Cat. No.: HY-134280
CAS No.: 477782-33-5
Synonyms: Nicotinamide 8-Br-hypoxanthine dinucleotide
Target:
Research Areas:
8-Br-NHD+ (Nicotinamide 8-Br-hypoxanthine dinucleotide) is a derivative of NAD+ (nicotinamide adenine dinucleotide) that acts as a potential substrate, competitive inhibitor or modulator of enzymes that interact with β-NAD+. 8-Br-NHD+ can be used to synthesize a cyclic ADP nucleotide (cADPR) analog .
Cat. No.: HY-W004305R
CAS No.: 629-80-1
Synonyms: Palmitaldehyde (Standard)
Cat. No.: HY-E70030
GlcNAc 1-P uridyltransferase (CjGlmU) is a sugar nucleotidyltransferase (SNT). GlcNAc 1-P uridyltransferase (CjGlmU) utilizes UTP and GlcNAc-1-P as its natural substrates, synthesizes UDP-GlcNAc. GlcNAc 1-P uridyltransferase (CjGlmU) has the potential for the research of antimicrobial agents .
Cat. No.: HY-P2296
Target:
Research Areas:
Cat. No.: HY-135773
CAS No.: 312928-72-6
Target:
Research Areas:
CRTh2 antagonist 3 is a potent chemoattractant receptor-homologous molecule expressed on Th2 cells (CRTh2) antagonist . CRTh2 antagonist 3 enhances the activity of PDK1 toward a short peptide substrate, with an EC50 of 2 μM and a Kd of 8.4 μM. CRTh2 antagonist 3 has the potential for cardiovascular inflammation .
Cat. No.: HY-W854392
CAS No.: 216672-17-2
Cat. No.: HY-W750190
CAS No.: 113712-08-6
Cat. No.: HY-145064
CAS No.: 2718971-29-8
Target:
Enpp-1-IN-6 is a potent inhibitor of ectonucleotide pyrophosphatase-phosphodiesterase 1 (enpp-1). The ENPP 1 has broad specificity and can cleave a variety of substrates, including phosphodiester bonds of nucleotides and nucleotide sugars and pyrophosphate bonds nucleotides and nucleotide sugars. Enpp-1-IN-6 has the potential for the research of cancer and infectious diseases (extracted from patent WO2021203772A1, compound 51) .
Cat. No.: HY-145065
Target:
Enpp-1-IN-7 is a potent inhibitor of ectonucleotide pyrophosphatase-phosphodiesterase 1 (enpp-1). The ENPP 1 has broad specificity and can cleave a variety of substrates, including phosphodiester bonds of nucleotides and nucleotide sugars and pyrophosphate bonds nucleotides and nucleotide sugars. Enpp-1-IN-7 has the potential for the research of cancer and infectious diseases (extracted from patent WO2021203772A1, compound 51) .
Cat. No.: HY-145069
CAS No.: 2718971-08-3
Target:
Research Areas:
Enpp-1-IN-8 is a potent inhibitor of ectonucleotide pyrophosphatase-phosphodiesterase 1 (enpp-1). The ENPP 1 has broad specificity and can cleave a variety of substrates, including phosphodiester bonds of nucleotides and nucleotide sugars and pyrophosphate bonds nucleotides and nucleotide sugars. Enpp-1-IN-8 has the potential for the research of cancer and infectious diseases (extracted from patent WO2021203772A1, compound 51) .
Cat. No.: HY-145070
CAS No.: 2718970-70-6
Target:
Enpp-1-IN-9 is a potent inhibitor of ectonucleotide pyrophosphatase-phosphodiesterase 1 (enpp-1). The ENPP 1 has broad specificity and can cleave a variety of substrates, including phosphodiester bonds of nucleotides and nucleotide sugars and pyrophosphate bonds nucleotides and nucleotide sugars. Enpp-1-IN-9 has the potential for the research of cancer and infectious diseases (extracted from patent WO2021203772A1, compound 51) .
Target:
Research Areas:
Enpp-1-IN-5 is a potent inhibitor of ectonucleotide pyrophosphatase-phosphodiesterase 1 (enpp-1). The ENPP 1 has broad specificity and can cleave a variety of substrates, including phosphodiester bonds of nucleotides and nucleotide sugars and pyrophosphate bonds nucleotides and nucleotide sugars. Enpp-1-IN-5 has the potential for the research of cancer and infectious diseases (extracted from patent WO2019046778A1/WO2021203772A1, compound 1) .
Cat. No.: HY-10446R
CAS No.: 146464-95-1
Target:
Research Areas:
Pralatrexate (Standard) is the analytical standard of Pralatrexate. This product is intended for research and analytical applications. Pralatrexate is an antifolate and is a potent dihydrofolate reductasean (DHFR) inhibitor with a Ki of 13.4 pM. Pralatrexate is a substrate for folylpolyglutamate synthetase with improved cellular uptake and retention. Pralatrexate has antitumor activities and has the potential for relapsed/refractory T-cell lymphoma treatment . Pralatrexate is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
Cat. No.: HY-161211
CAS No.: 863564-16-3
Research Areas:
HSD17B13-IN-7 (compound 1), a fluorophenol-containing compound, is a potent HSD17B13 inhibitor with IC50s of 0.18 μM and 0.25 μM β-estradiol and Leukotriene B4 as substrates, respectively. HSD17B13-IN-7 is a potent N-methyl-D-aspartate (NMDA) NR2B receptor antagonist. HSD17B13-IN-7 has the potential for non-alcoholic fatty liver disease research .
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
